CD9阻断抑制高危儿童B细胞前体急性淋巴细胞白血病进展并增强化疗敏感性
研究在儿童B细胞前体急性淋巴细胞白血病(BCP-ALL)队列中发现CD9阳性患者5年无复发生存率显著低于CD9阴性患者,且CD9阳性独立预测不良生存。在NOD/SCID小鼠模型中,CD9抗体显著抑制高危和难治性BCP-ALL疾病进展且不影响造血干细胞植入,与常规化疗联用进一步降低白血病负荷并延长生存。机制上CD9阻断抑制增殖、诱导G0/G1期阻滞、激活p38并增强化疗诱导的凋亡。
要点
- CD9阳性是儿童BCP-ALL独立不良预后因素,可结合泼尼松反应和细胞遗传学优化分层。
- CD9抗体在临床前模型中抑制高危/难治性BCP-ALL进展且不损害造血干细胞植入。
- 抗CD9联合常规化疗进一步降低白血病负荷并延长动物生存。
核心结论
- CD9是儿童BCP-ALL的新预后标志物,CD9抗体在临床前模型中显示对高危和难治性疾病的疗效。
研究设计与样本
- 研究纳入儿童BCP-ALL患者队列进行预后分析,并在NOD/SCID小鼠中移植CD9+细胞系及高危/难治患者原代白血病细胞进行临床前干预实验。
主要发现
- CD9+病例5年无复发生存率显著低于CD9-病例。
- 多因素分析显示CD9阳性独立预测不良生存,可与泼尼松反应和细胞遗传学状态联合优化患者分层。
- CD9抗体显著抑制CD9+细胞系及高危/难治患者原代白血病细胞移植小鼠的疾病进展,且未损害造血干细胞植入。
- 抗CD9联合常规化疗进一步降低白血病负荷并延长动物生存。
- CD9阻断抑制白血病细胞增殖、诱导G0/G1期阻滞、激活p38并增强化疗诱导的凋亡;CD9与整合素VLA-4相互作用并调控对VCAM-1的亲和力。
临床怎么用
- CD9免疫表型可用于儿童BCP-ALL预后分层,辅助识别高危患者。
- CD9靶向抗体联合化疗可能成为高危和难治性儿童BCP-ALL的潜在治疗策略。
局限性
- 疗效数据来自NOD/SCID小鼠临床前模型,尚未在人体临床试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD9 has been implicated in cancer progression but its prognostic relevance and therapeutic potential in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) are largely unknown. In a cohort of pediatric BCP-ALL patients, we found that CD9+ cases had a significantly lower 5-year relapse-free survival rate than CD9- cases. Multivariate analysis demonstrated that CD9 positivity independently predicted inferior survival outcomes, and could be applied with established prognostic features, including prednisone response and cytogenetic status, to refine patient stratification. Administration of CD9 antibody substantially suppressed disease progression in NOD/SCID mice xenografted with CD9+ cell lines and primary leukemic blasts from patients with high-risk and refractory BCP-ALL, without compromising hematopoietic stem cell engraftment. Combination of anti-CD9 with conventional chemotherapy further reduced leukemic burden and prolonged animal survival. Mechanistically, CD9 blockade inhibited leukemic cell proliferation, induced G0/G1 cell cycle arrest, activated p38, and enhanced chemotherapeutic agent-induced apoptosis. Further, CD9 physically interacted with integrin very late antigen-4, regulated affinity to vascular cell adhesion molecule-1, and was involved in leukemia-stroma interaction. Collectively, our study established CD9 as a new prognostic marker, validated the preclinical efficacy of CD9 antibody, and laid the foundation for clinical development of CD9-targeted therapy for high-risk and refractory pediatric BCP-ALL.
引用
- Leung KT, Zhang C, Chan KYY, et al. CD9 blockade suppresses disease progression of high-risk pediatric B-cell precursor acute lymphoblastic leukemia and enhances chemosensitivity. Leukemia. 2019. PMID: 31624373. doi:10.1038/s41375-019-0593-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。